Fig. 2.

Achievement over time of resolution of enthesitis, resolution of dactylitis, improvement in PASI 90, and reduction in mNAPSI. PASI 90 reported only for patients with psoriasis-affected BSA ≥ 3 at baseline. mNAPSI reported only for patients with nail psoriasis at baseline. Resolution of enthesitis and dactylitis reported as pooled results from the KEEPsAKE 1 and 2 studies for patients with enthesitis (LEI > 0) or dactylitis (LDI > 0) at baseline. BSA body surface area, CI confidence interval, MMRM mixed-effect model for repeated measures, LDI Leeds Dactylitis Index, LEI Leeds Enthesitis Index, mNAPSI modified Nail Psoriasis Severity Index, NRI-C nonresponder imputation incorporating multiple imputations to handle missing data due to COVID-19, NRI-MI nonresponder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as nonresponders, including missing data and patients who received rescue therapy, PASI 90 ≥ 90% improvement from baseline in Psoriasis Area and Severity Index, PBO placebo, RZB risankizumab